Pharmaceuticals company Blue Jet Healthcare announced Q1FY26 results Revenue from operations for Q1FY26 stood at Rs 3,548 million which grew 4.2% QoQ compared to Rs 3,404 million in Q4FY25; up 117.8% on YoY basis compared to Rs 1,629 million in Q1FY25. This growth is mainly driven by higher sales in PI & API product category and gross margin of 48.4% in Q1FY26. EBITDA for the quarter came at Rs 1,210 million, down 13.6% QoQ compared to Rs 1,400 in Q4FY25; up 173.3% YoY compared to Rs 443 million in Q1FY25. EBITDA margin for the quarter came at 34.1% as compared to 41.4% in Q4FY25 down 701 bps; 27.2% in Q1FY25, up 693 bps YoY. PAT for the quarter was at Rs 912 million, which degrew 17.2% QoQ compared to Rs1,101 million; up 141.3% compared to Rs 378 million in Q1FY25. PAT margin for the quarter came at 25.7% as compared to 32.3%, down 664 bps; 23.2% in Q1FY25, up 251 bps YoY. Reduction in QoQ is primarily attributable to a drop in gross margin to 48.4% in Q1FY26 from 54.7% in Q4FY25, driven by a shift in product mix and reduced inventory levels, resulting in lower overhead absorption during Q1FY26. Shiven Arora, Managing Director, Blue Jet Healthcare, said: “Blue Jet Healthcare clocked a revenue of Rs 3,548 million, a growth of 117.8% YoY with EBITDA coming in at Rs 1,210 million. This was primarily driven by the ramp up in PI & API product categories. The robust growth, coupled with strong EBITDA margins, reflects our focus on operational efficiency and a solid business foundation. Looking ahead, we remain confident in our growth strategy, driven by capacity expansions, enhanced R&D; capabilities, and a robust pipeline of high-value products. We are committed to delivering long-term value to our stakeholders through consistent performance, innovation, and strategic investments.” Result PDF